This company is no longer in business. Investors can get details about any potential exits or failures here.

Eclipse Diagnostics

Eclipse Diagnostics

Early Stage

Preventing Stroke At Home

Preventing Stroke At Home


Raised to Date: Raised: $171,750

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Farming & Agriculture

Tech Sector



Los Angeles, California

Who Should Be Interested:
Are you a stroke survivor, or a diabetic patient? Do you know someone who has experienced the scariness of a stroke? If you are, or if you have, then investing in Eclipse Diagnostics could be the move for you. They’re developing an innovative new technology that will help prevent strokes at home.

The Company:
Eclipse Diagnostics wants to truly help eclipse the surprise of strokes. They’re developing an easy-to-use home device to monitor the risk of stroke -- and hopefully prevent it. There is a blood marker that, when elevated, indicates a high risk of stroke. By monitoring this blood marker at least once a week, patients will be able to see early warning signs and visit a doctor for further diagnostics. Eclipse’s patented technology and device is easy to use. Users simply prick their finger for a drop of blood, put it into the disposable one-time-use test strip, and a bluetooth device reads the strip. The device connects to a smartphone app that gathers and processes the information, and if the user’s biomarkers reach dangerous levels, the app will provide a warning and alert. This is the first device of its kind to allow patients to monitor their stroke risk at home -- and take preventable action as a result.

The Bottom Line:
Stroke is currently the fifth leading cause of death in the US -- but up to 80% of strokes can be prevented. Eclipse Diagnostics is giving diabetics and at-risk patients the chance to monitor early warning signs, reach out to a doctor when needed...and ultimately prevent the stroke from happening at all.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Eclipse Diagnostics 04/28/2020 StartEngine $11,189,805 $179,058 Equity - Common Funded RegCF
Eclipse Diagnostics 10/30/2018 StartEngine $10,000,000 $171,750 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Eclipse Diagnostics on StartEngine
Platform: StartEngine
Security Type: Equity - Common
Valuation: $10,000,000
Price per Share: $10.00

Follow company

Follow Eclipse Diagnostics on StartEngine

Buy Eclipse Diagnostics's Deal Report

Warning: according to the close date for this deal, Eclipse Diagnostics may no longer be accepting investments.

Eclipse Diagnostics Deal Report

Get KingsCrowd’s comprehensive report on Eclipse Diagnostics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Eclipse Diagnostics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Eclipse Diagnostics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge